151 related articles for article (PubMed ID: 8927346)
1. [Cyclosporin-A therapy in autoimmune diseases].
Patakfalvi A
Orv Hetil; 1996 Sep; 137(35):1921-7. PubMed ID: 8927346
[TBL] [Abstract][Full Text] [Related]
2. [Cyclosporin in autoimmune diseases].
Follath F; Fontana A; Leumann E; Michel BA; Miescher PA; Schreier M; Schroeder M; Wenk M
Schweiz Med Wochenschr; 1994 Jul; 124(27-28):1232-9. PubMed ID: 8052828
[TBL] [Abstract][Full Text] [Related]
3. [Problems associated with the use and monitoring of cyclosporin. Experience at a Clinical Pharmacology Service].
Loffreda A; Contaldi C; Santis DD; Marabese I; Chiaiese C; Formato P; Motola G; Russo F; D'Alessio O; Lampa E; Rossi F
Minerva Med; 1997 Dec; 88(12):543-9. PubMed ID: 9540786
[TBL] [Abstract][Full Text] [Related]
4. [Cyclosporin in autoimmune diseases].
Frey FJ
Schweiz Med Wochenschr; 1990 May; 120(21):772-86. PubMed ID: 2190313
[TBL] [Abstract][Full Text] [Related]
5. [Amniotic membrane transplantation and high-dose systemic cyclosporin A (Sandimmun optoral) for Mooren's ulcer].
Spelsberg H; Sundmacher R
Klin Monbl Augenheilkd; 2007 Feb; 224(2):135-9. PubMed ID: 17309011
[TBL] [Abstract][Full Text] [Related]
6. [Cyclosporin].
Nojima Y
Nihon Rinsho; 2005 May; 63 Suppl 5():669-72. PubMed ID: 15954427
[No Abstract] [Full Text] [Related]
7. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?
Manna R; Verrecchia E; Fonnesu C; Giovinale M; De Socio G; Curigliano V; Cerquaglia C; Soriano A; Granata M; Migliore A; Massafra U; Gasbarrini G
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():63-9. PubMed ID: 19530514
[TBL] [Abstract][Full Text] [Related]
8. Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up.
Boubouka CD; Charissi C; Kouimintzis D; Kalogeromitros D; Stavropoulos PG; Katsarou A
Acta Derm Venereol; 2011 Jan; 91(1):50-4. PubMed ID: 21264453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
10. [Headache associated with cyclosporin ina patient with membranous glomerulonephritis].
Borrás Blasco J; Enríquez R; Amorós Amorós F; Navarro Ruiz A; Conesa García V; González Delgado M
Farm Hosp; 2004; 28(6):454-7. PubMed ID: 15628949
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of cyclosporin in allogeneic stem cell transplantation.
Duncan N; Craddock C
Bone Marrow Transplant; 2006 Aug; 38(3):169-74. PubMed ID: 16751787
[TBL] [Abstract][Full Text] [Related]
12. [Cyclosporin in treatment of glomerular diseases].
Krieter DH; Müller GA
Internist (Berl); 1996 Jan; 37(1):84-8. PubMed ID: 8837833
[No Abstract] [Full Text] [Related]
13. Cardiovascular effects of cyclosporin treatment in an experimental model.
Tavares P; Reis F; Ribeiro CA; Teixeira F
Rev Port Cardiol; 2002 Feb; 21(2):141-55. PubMed ID: 11963284
[TBL] [Abstract][Full Text] [Related]
14. [Cyclosporin A in inflammatory rheumatic diseases].
Gross WL; Rob PM
Internist (Berl); 1996 Jan; 37(1):91-7. PubMed ID: 8837835
[No Abstract] [Full Text] [Related]
15. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
16. [The combination of cyclosporin A and fluocortolone in the treatment of autoimmune diseases].
Aresu G; Pascalis L; Pia G
Clin Ter; 1989 Oct; 131(1):3-21. PubMed ID: 2531058
[TBL] [Abstract][Full Text] [Related]
17. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
Atakan N; Erdem C
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):240-6. PubMed ID: 9883436
[TBL] [Abstract][Full Text] [Related]
18. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.
Galeazzi M; Bellisai F; Giannitti C; Manganelli S; Morozzi G; Sebastiani GD
Ann N Y Acad Sci; 2007 Sep; 1110():544-9. PubMed ID: 17911470
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
Cantarovich M; Besner JG; Fitchett DH; Latter DA
Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome.
Borel JF
Clin Nephrol; 1991; 35 Suppl 1():S23-30. PubMed ID: 1860262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
